Splash Beverage Group (NYSE: SBEV) adds CannEpil veterinary program
Rhea-AI Filing Summary
Splash Beverage Group, Inc. entered into an addendum with Argent BioPharma Limited to its exclusive global CannEpil® license, expanding the field of use to include veterinary applications, revising royalties to 10% of Net Revenue from veterinary uses and 15% of Net Revenue from human uses, and extending certain contractual deadlines.
The company now holds exclusive worldwide rights to develop, manufacture, commercialize, market and distribute CannEpil for veterinary diseases, initially focusing on companion-animal oncology and chronic pain. It plans to pursue FDA Center for Veterinary Medicine INAD and Conditional Approval pathways and is finalizing a joint venture to lead the veterinary program.
Positive
- None.
Negative
- None.
Filing Explained
The amendment expands Splash’s exclusive CannEpil license to veterinary uses and sets royalties at 10% of veterinary net revenue and 15% of human net revenue; the related development and FDA-approval process remains planned, not approved or commercialized.
8-K Event Classification
3 items: 1.01, 7.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Veterinary royalty rate: 10% of Net Revenue
Human royalty rate: 15% of Net Revenue
Vet pain management market 2024: $2.6 billion
+5 more
8 metrics
Veterinary royalty rate
10% of Net Revenue
Royalty on net revenues from veterinary applications of CannEpil
Human royalty rate
15% of Net Revenue
Royalty on net revenues from human applications of CannEpil
Vet pain management market 2024
$2.6 billion
Global veterinary pain management market value in 2024
Vet pain management market 2030
$3.8 billion
Projected global veterinary pain management market by 2030
Vet oncology market range
$900 million–$1.7 billion
Estimated global veterinary oncology market size range
Dogs developing cancer
1 in 4 dogs
Proportion of dogs expected to develop cancer during their lifetime
Older dogs with cancer
Approximately half
Approximate share of dogs over age ten that develop cancer
Annual U.S. dog cancer cases
6 million
Estimated number of dogs diagnosed with cancer each year in the U.S.
Key Terms
Investigational New Animal Drug (INAD), Conditional Approval, Investigational New Drug (IND), European Union Good Manufacturing Practice (EU-GMP), +2 more
6 terms
Investigational New Animal Drug (INAD) regulatory
"through the FDA Center for Veterinary Medicine’s Investigational New Animal Drug (INAD)"
Investigational New Animal Drug (INAD) is a regulatory designation and file that allows a company to study a new veterinary drug in animals under government oversight before it can be approved for sale. It documents permitted testing plans, safety and efficacy data collection, and manufacturing controls. For investors, an INAD indicates a drug is in the formal development and review phase, affecting timelines, development costs, regulatory risk, and the potential size and timing of future market opportunity, analogous to a permit to prototype before commercial launch.
Conditional Approval regulatory
"pursue U.S. regulatory approval through the FDA Center for Veterinary Medicine’s INAD and Conditional Approval pathways"
Conditional approval is a formal confirmation that a product or plan is permitted to proceed, provided certain specified requirements are met within a designated timeframe. For investors, it signals that approval is nearly complete but depends on the fulfillment of specific conditions, which could influence the final outcome or timeline. This status helps stakeholders assess the likelihood of success while identifying any remaining hurdles.
Investigational New Drug (IND) regulatory
"assigned an Investigational New Drug (IND) application number by the U.S. Food and Drug Administration"
An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.
European Union Good Manufacturing Practice (EU-GMP) technical
"manufactured under European Union Good Manufacturing Practice (EU-GMP) standards"
companion-animal oncology medical
"initially evaluate CannEpil for veterinary applications in companion-animal oncology and chronic pain management"
Net Revenue financial
"10% of Net Revenue attributable to veterinary applications and 15% of Net Revenue attributable to human applications"
Net revenue is the total amount of money a company earns from selling its products or services after subtracting any returns, discounts, or refunds. It shows how much actual income the company keeps from its sales. This figure is important because it reveals the true earnings from business activities, helping people understand how well the company is doing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What agreement did Splash Beverage Group (SBEV) amend regarding CannEpil?
Splash Beverage Group amended its exclusive global license agreement for CannEpil® with Argent BioPharma Limited. The addendum expands the field of use to veterinary applications, adjusts royalty rates, and extends certain deadlines under the original July 6, 2026 license agreement.
What royalty rates apply to Splash Beverage Group (SBEV) under the CannEpil addendum?
Under the addendum, Splash will pay Argent BioPharma a 10% royalty on net revenues from veterinary applications and a 15% royalty on net revenues from human applications. These rates apply to Net Revenue as defined in the underlying license agreement.
How is Splash Beverage Group (SBEV) expanding CannEpil into veterinary therapeutics?
Splash expanded its exclusive CannEpil license to cover veterinary diseases and conditions, with exclusive worldwide rights to develop, manufacture, commercialize, market and distribute. Initial efforts will evaluate CannEpil for companion-animal oncology and chronic pain, with a focus on canine indications.
What market opportunities does SBEV target with CannEpil’s veterinary program?
The company cites a global veterinary pain management market of about $2.6 billion in 2024, projected to reach $3.8 billion by 2030. It also references companion-animal oncology market estimates between approximately $900 million and $1.7 billion, highlighting significant potential patient populations.
Which regulatory pathways will Splash Beverage Group (SBEV) pursue for veterinary CannEpil?
Splash intends to pursue U.S. approval for veterinary CannEpil through the FDA Center for Veterinary Medicine’s Investigational New Animal Drug (INAD) and Conditional Approval pathways. Actual timelines, indications and requirements will be determined after engagement with regulators.
What risks did Splash Beverage Group (SBEV) highlight about the CannEpil veterinary program?
The company notes risks including whether the license and development efforts deliver expected benefits, ability to secure and protect intellectual property, raising required capital, complying with extensive regulations, executing a planned joint venture, and the uncertainty of obtaining any regulatory approval for CannEpil.